Skip to content

Study · Animal study (in vivo) · rat · 1988

4 results

One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.

Okada H, Heya T, Ogawa Y, Shimamoto T

The Journal of pharmacology and experimental therapeutics1 Feb 1988Cited by 60 (Europe PMC)

PMID3126294 (opens in a new tab)DOI10.1016/s0022-3565(25)24466-4 (opens in a new tab)PepBankPUB-03126294
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, leuprolide microcapsules exhibited pseudo-zero-order release from the injection site for 1 month.

    In plain wordsIn rats, leuprolide microcapsules released drug at a near-constant rate for 1 month.

    Peptide
    Leuprolide
    Outcome
    Not applicableDrug release kinetics
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and intramuscularAs given in this study (rat).

    Source sentences

    Summary
    In rats, the microcapsules exhibited a pseudo-zero order release from the injection site for 1 month after being administered s.c. and i.m., and maintained effective constant serum levels of the analog during the 4-week treatment.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, leuprolide microcapsules maintained effective constant serum drug levels during 4-week treatment.

    In plain wordsIn rats, leuprolide microcapsules maintained constant effective blood drug levels during 4-week treatment.

    Peptide
    Leuprolide
    Outcome
    Not applicableSerum drug levels
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and intramuscular · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In rats, the microcapsules exhibited a pseudo-zero order release from the injection site for 1 month after being administered s.c. and i.m., and maintained effective constant serum levels of the analog during the 4-week treatment.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, one leuprolide microcapsule injection suppressed luteinizing hormone, follicle-stimulating hormone and estradiol for more than 4 weeks.

    In plain wordsIn female rats, one leuprolide microcapsule injection suppressed luteinizing hormone, follicle-stimulating hormone and estradiol for more than 4 weeks.

    Peptide
    Leuprolide
    Outcome
    DecreaseLuteinizing hormone, follicle-stimulating hormone and estradiol
    Study

    ratn: not reported in source

    Jones experimental endometriosis model in female rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 micrograms/kg/day as leuprolide acetateAs given in this study (rat).

    Source sentences

    Summary
    A single injection of the microcapsules (100 micrograms/kg/day as leuprolide acetate) suppressed luteinizing hormone, follicle-stimulating hormone and estradiol for more than 4 weeks, and caused a dramatic regression of growth of Jones experimental endometriosis model in female rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female rats with experimental endometriosis, one leuprolide microcapsule injection caused marked regression of lesion growth.

    In plain wordsIn female rats with experimental endometriosis, one leuprolide microcapsule injection markedly reduced lesion growth.

    Peptide
    Leuprolide
    Outcome
    DecreaseExperimental endometriosis growth
    Study

    ratn: not reported in source

    Jones experimental endometriosis model in female rats
    Outcome group
    Endometriosis Growth · Reproductive and sexual health
    Studied dose
    100 micrograms/kg/day as leuprolide acetateAs given in this study (rat).

    Source sentences

    Summary
    A single injection of the microcapsules (100 micrograms/kg/day as leuprolide acetate) suppressed luteinizing hormone, follicle-stimulating hormone and estradiol for more than 4 weeks, and caused a dramatic regression of growth of Jones experimental endometriosis model in female rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.